Analytical Excellence
Seqens provides GMP testing on Active Pharmaceutical Ingredients (API) and excipients. We have an extensive team focused on the development and clinical…
Read more
R&D Services
SEQENS operates 7 R&D excellence centers in Europe and North America. More than 250 scientists, engineers and experts work on tailor made solutions with our internal or external customers and ensure their production at the manufacturing stage. SEQENS offers complete and fully integrated R&D services to support its customers’ projects from early stages to commercial manufacturing in total compliance with the highest quality, safety and environmental standards. The key to success is our commitment to delivering best-in-class services.
Our R&D Services offer
Flow Chemistry
Approximately 2,800 active pharmaceutical ingredients (APIs) are currently marketed, 70% of which being synthetic chemical molecules.Their complexity tends to increase:…
Read more
Computational predictive toxicology and mechanism of action investigation
Harmonic Pharma has developed computational solutions that combine computational predictive toxicology and mechanism of action investigation. Many compounds currently in development will never…
Read more
Multi-catalysis
Designing the most cost-efficient routes of synthesis is a primary consideration at Seqens. Catalysis is widely used to accelerate reactions, optimize yield…
Read more
Late Phase development
Seqens is a world leader in pharmaceutical synthesis, capable of providing full CMC support to prepare for phase III clinical trials and…
Read more
Early Phase development
Seqens provides active pharmaceutical ingredient (API) and drug substance development services to support emerging and large pharmaceutical customers in human and animal…
Read more
Custom ingredients
Seqens has longstanding experience in up-scaling and custom manufacturing of chemicals for various industries (fine chemicals, lubricants, electronics…). We offer our expertise,…
Read more
Cosmetics & Personal care
Cosmetic products, which are high consumption products, are the outcome of an industrial sector with diversified know-how, particularly in the supply of…
Read more
High-Potency APIs (HPAPIs)
Seqens has been involved in the small-scale production of potent compounds for many years. As an element of our growth strategy, the…
Read more
Solid state characterization
The need to investigate the solid-state properties of Active Pharmaceutical Ingredient (API) has become important in the pharmaceutical development industry.
Read more
Artificial Intelligence
ApI : Artificial Intelligence and simulation tool to accelerate API development.
Read more
Toxicology
GenEvolutioN is an expert spin off, dedicated to in vitro genetic toxicology and toxicology expertise using new Human cell models.
Read more
Aramon’Lab (Drug Delivery Polymers)
Seqens strongly believes in the potential of new cutting-edge technologies to improve the use and efficiency of existing APIs. To support its…
Read more
Biocatalysis
The multidisciplinary Seqens team provides competitive innovation to the industry by developing bio-based industrial solutions. Enzymes / biocatalysts Seqens…
Read more
Applicative R&D
Seqens produces essential chemicals used in everyday products, and has developed applicative R&D competencies to improve products performances on specific key…
Read more
#News
General
Seqens to Unveil New Innovation and Development Center of Excellence
Seqens, an integrated global leader in pharmaceutical synthesis and specialty ingredients, will open a 34,000-square-meter lab today that is close to Paris…
Read more
Events / Press Release
Seqens’Lab Unveiling
Seqens is unveiling its main innovation and development centre in the presence of Ms. Agnès Pannier-Runacher, Secretary of State to the Minister…
Read more
General / Press Release / Products & Technologies
Covid-19
SEQENS mobilizes its innovation to support the unprecedented research on the COVID-19 and prepares its unique industrial network for anti-virus production, for example hydroxychloroquine.
Pending the availability of a vaccine, which will necessarily take time, the race against the clock is underway for the identification and…
Read more
General / Press Release
Porcheville obtained its GMP certificate
SEQENS R&D Center in Porcheville, France, confirms its status as a center of excellence On 21 January 2019, the French National Agency for…
Read more
General / Protéus
Applying Enzymatic Synthesis for Chiral Molecules
Pharma’s Almanac Magazine Advances in our understanding of enzymatic transformations and the increased availability of enzymes engineered for use in fine chemical synthesis…
Read more
General
GenEvolution: awarded at the “Entrepreneur Prize” trophies of the Grand Paris Seine & Oise
On the evening of Tuesday, March 19, 2019, GenEvolution, based at the Porcheville Seqens site, received two awards: the Public Prize and the Innovation…
Read more
General / Products & Technologies
Interview of Christelle FERRAGUT & Guillaume NOTHEAUX (Advanced Specialties) about Lubricant Business Line.
Lubricant additives & grease at Seqens “We do not sell a molecule, we sell a performance.” How much do you know Lubricant additives ? An…
Read more
General / Products & Technologies / Protéus
Covid-19
What flow chemistry and biocatalysis bring to synthesize a typical small molecule candidate against Covid-19 epidemic
Efficient and safe process design combining SEQENS technical capabilities: Brilacidin as a case study As already mentioned in our previous article (“Seqens…
Read more